EGFR-TKI maintenance therapy for advanced non-small-cell lung cancer with positive EGFR mutation

CAO Jingxu; LI Ren; YU Liquan; SU Dan; XU Yang; and BU Jie

PDF(500 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2015, Vol. 26 ›› Issue (10) : 988-990.

ORIGINAL ARTICLES

EGFR-TKI maintenance therapy for advanced non-small-cell lung cancer with positive EGFR mutation

CAO Jingxu, LI Ren, YU Liquan, SU Dan, XU Yang, and BU Jie

Author information +

History +

Abstract

Objective To investigate the efficacy and safety of EGFR-tyrosine-kinase inhibitor(EGFR-TKI)as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) and positive EGFR mutation. Methods Thirty-two patients who suffered from advanced NSCLC with EGFR mutation-positive were given EGFR-TKIS (Gefitinib, Taceva or Icotinib) as maintenance therapy following first-line chemotherapy and no disease progression. Clinical efficacy, progression-free survival (PFS), overall survival (OS) and adverse events were analyzed. Results Complete remission(CR), partial remission(PR), stable disease(SD) and progressing disease(PD)were observed in 3, 7, 18 and 4 cases, respectively. Response rate (RR) was 31.3% and disease control rate (DCR) was 87.5% in the group. Median PFS was 14.9 months(95% CI:11.93~17.87) and mOS was 25.1 months (95% CI:20.8~29.3). The most common adverse events were rash (37.5%) and diarrhea (15.6%). Conclusions EGFR-TKIs as maintenance therapy in the patients with advanced NSCLC and EGFR mutation-positive is effective and safe.

Key words

non-small-cell lung cancer / EGFR-tyrosine-kinase inhibitor / maintenance therapy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

CAO Jingxu, LI Ren, YU Liquan, SU Dan, XU Yang, and BU Jie. EGFR-TKI maintenance therapy for advanced non-small-cell lung cancer with positive EGFR mutation[J]. Medical Journal of the Chinese People Armed Police Forces. 2015, 26(10): 988-990

References

[1] Siegel R, Miller K, Jemal A. Cancer statistics:2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
[2] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范[J].中华肿瘤杂志,2015,37(1):67-78.
[3] Ramalingam S, Belani C P. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions [J]. J Oncologist, 2008, 13(suppl1): 5-13.
[4] Marino P, Pampallona S, Preatoni A, et al. Chemo-therapy vs supportive care in advanced non-cell lung cancer: Results of a meta-analysis of the literature [J]. Chest, 1994,106(3):861-865.
[5] Pirker R, Pereial J, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX) open-label randomized phase Ⅲ trial [J]. Lancet, 2009, 373(9674): 1525-1531.
[6] Perol M, Chouaid C, Milleron B J, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase 3 study [J]. Clin Oncol, 2010,28(suppl):540s.
[7] 李艳,郭其森. 晚期非小细胞肺癌维持治疗进展[J]. 中华肿瘤防治杂志, 2014, 21 (10): 800-804.
[8] Brodowicz T, Krzakowski M , Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial [J]. Lung Cancer, 2006, 52: 155-163.
[9] Stinchcombe T, Socinski M. Maintenance therapy in advanced non-small cell lung cancer: current status and future implications [J]. J Thorac Oncol, 2011, 6(1): 174-182.
[10] Ciuleanu T, Brodowicz T, Zielinski C, et al. Manintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized double-blind, phase 3 study [J]. Lancet, 2009, 374: 1432-1440.
[11] Goldie J H, Colkman A J. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate[J] . Cancer Treat Rep, 1979, 63(11-12): 1727-1733.
[12] Fidias P M, Dakhil R, Lyss P, et al. Ⅲ study of immediate compared with delayed docetaxal after front-line therapy with gemeitabine plus carboplatin in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(4):591-598.
[13] Mencoboni M, Bergaglio M, Serra M, et al. Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer[J]. Anticancer Res, 2007, 27(6c): 4425-4429.
[14] Zhou C, Wu Y L, Chen C, et al. Updated efficacy and quality of life (Qol) analyses in OPTIMAL, a phase 3, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive(EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC) [J]. J Clin Oncol,29(suppl): 2011.
[15] Maemondo M, Inoue A, Kobayashi K, et al. Cefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med, 2010, 362(25): 2380-2388.
[16] Mok T S , Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med,2009, 361(10):947 - 957.
[17] Zhou C, Wu Y L, Chen G, et al. Erlotinib versus Chemotherapy as first-line treatment for Patients with advanced EGFR mutation - positive non-small-cell lung cancer (OPTIMAL,CTONG-0802): a multicentre, open-label, randomized, phase 3 study [J]. Lancet Oncol, 2011, 12(18): 735-742.
[18] Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung caner:A multicentre, randomized , placebo-controlled phase 3 study[J]. Lancet Oncol, 2010, 11(6): 521-529.
[19] 钱晓涛,赵腊梅,何圆,等. 吉非替尼维持治疗晚期非小细胞肺癌的疗效[J]. 实用临床医学,2014, 15(9):5-14.
[20] Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer(INFORM; C-TONG 0804)[J]. J Clin Oncol, 2011, 29(Suppl:Abstract):7511.